Posted on February 26, 2015 by Sitemaster
Results from a small trial of Barvarian Nordic’s investigational drug Prostvac — used in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy) — appear to have shown relatively dramatic effects in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipilimumab, mCRPC, metastatic, Prostvac, Yervoy | 6 Comments »
Posted on May 20, 2011 by Sitemaster
Two drugs already approved in the US that either have been or may be used in the treatment of prostate cancer have now been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, ipilimumab, Xgeva, Yervoy | 2 Comments »
Posted on March 25, 2011 by Sitemaster
The U.S. Food & Drug Administration today approved ipilimumab (brand name Yervoy®) for the treatment of patients with metastatic melanoma (an aggressive form of skin cancer). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: ipilimumab, Yervoy | 8 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 